Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 15 Leukemia, Myeloid, Chronic-Phase 6 Neoplasm Metastasis 4 Neoplasms 3 Philadelphia Chromosome 2 Ovarian Neoplasms 2 Myeloproliferative Disorders 2 Leukemia 2 Synovitis, Pigmented Villonodular 1 Sarcoma 1 Recurrence 1 Peritoneal Neoplasms 1 Neoplasm, Residual 1 Melanoma 1 Leukemia, Myeloid 1 Hematologic Diseases 1 Giant Cell Tumor of Tendon Sheath 1 Genital Neoplasms, Female 1 Gastrointestinal Stromal Tumors 1 Fallopian Tube Neoplasms 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Chordoma 1 Cholangiocarcinoma 1 Breast Neoplasms 1 Blast Crisis 1 Appendiceal Neoplasms 1 Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Doxorubicin 26 pembrolizumab 24 Radiotherapy 20 Cyclophosphamide 18 Magnetic Resonance Spectroscopy 17 Specimen Handling 14 Nivolumab 14 Gemcitabine 13 Ifosfamide 12 Surgical Procedures, Operative 11 Biopsy 11 Radiation 10 X-Rays 8 Temozolomide 8 Ipilimumab 8 pazopanib 7 fludarabine 7 cabozantinib 7 Irinotecan 7 tazemetostat 6 liposomal doxorubicin 6 Trabectedin 6 Surveys and Questionnaires 6 Phantoms, Imaging 6 Blood Specimen Collection 6 olaparib 5 eribulin 5 atezolizumab 5 anlotinib 5 Vincristine 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Sarcoma × nilotinib × 1 year × Clear all

NCT03784014 2026-04-29

MULTISARC

Institut National de la Santé Et de la Recherche Médicale, France

Phase 3 Completed

Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡